Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients.
Active, not recruiting
- Conditions
- COVID-19SARS-CoV-2 Infection
- Interventions
- Drug: Molnupiravir
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Serap Yavuz
- Target Recruit Count
- 2600
- Registration Number
- NCT06223932
- Locations
- 🇹🇷
Istanbul Haseki Training and Research Hospital, Istanbul, Turkey
🇹🇷Istanbul University, Istanbul Faculty of Medicine, Department of Infectious Disease, Istanbul, Fatih, Turkey
🇹🇷Cerrahpasa Faculty of Medicine Infectious Disease Departament, Istanbul, Fatih, Turkey
© Copyright 2025. All Rights Reserved by MedPath